<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107744</url>
  </required_header>
  <id_info>
    <org_study_id>H0330</org_study_id>
    <secondary_id>R01HL068057</secondary_id>
    <nct_id>NCT00107744</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Protein and Blood Pressure</brief_title>
  <acronym>ProBP</acronym>
  <official_title>Clinical Trial of Protein and Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, double-blind, controlled trial is to examine the effect of
      soybean protein supplementation on blood pressure in persons with prehypertension or stage-1
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Epidemiologic studies suggest that vegetable protein intake is inversely related
      to blood pressure.

      Objectives: To examine the effect of soybean protein supplementation on blood pressure in
      persons with prehypertension or stage-1 hypertension

      Design: Randomized, double-blind, controlled trial

      Study Participants: 350 participants, aged 35-64 years, with an initial untreated systolic
      blood pressure of 130-159 mmHg and/or diastolic blood pressure of 80-99 mmHg

      Intervention: Study participants will be randomly assigned to take 40-grams of isolated
      soybean protein supplements per day or complex carbohydrate control for 12 weeks.

      Outcomes: Blood pressure measurements will be obtained using random-zero sphygmomanometers at
      baseline and during the trial at weeks 6 and 12. Net changes in systolic and diastolic blood
      pressure before and after the intervention is the primary outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The trial participants were assigned to take 40 g/d soy protein, milk protein, or carbohydrate supplementation each for 8 weeks in a random order. A 3-week washout period was implemented between the interventions.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The randomization assignment list was generated by a computer program that could only be accessed by the study data coordinator. Apart from the data coordinator, all research personnel, including investigators, study coordinators, and BP technicians, and the study participants were unaware of treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average Systolic Blood Pressure at 8 Weeks</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
    <description>The change of systolic blood pressure was calculated as the mean of 6 blood pressure values from two 8-week visits minus the mean of 6 values from 2 baseline visits within each intervention phase. At each visit, 3 BP values were measured with a Hawksley random-zero sphygmomanometer by trained and certified observers who were masked to group assignment. BP readings were taken from the right arm with appropriately sized cuffs after the participant had been seated quietly for 5 minutes. The participant was instructed not to eat, smoke, drink alcohol, or exercise for at least 30 minutes before their BP measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum LDL-cholesterol at 8 Weeks</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
    <description>Change in serum LDL-cholesterol was calculated as LDL-cholesterol at 8 weeks minus LDL-cholesterol at baseline. Over-night fasting serum LDL-cholesterol was measured with an enzymatic method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight at 8 Weeks</measure>
    <time_frame>Baseline and 8 Weeks</time_frame>
    <description>Body weight was measured by trained staff using a standard protocol at week 8.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Soy protein-milk protein-carbohydrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk protein-carbohydrate-soy protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbohydrate-soy protein-milk protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy protein-milk protein-carbohydrate</intervention_name>
    <description>40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks</description>
    <arm_group_label>Soy protein-milk protein-carbohydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Milk protein-carbohydrate-soy protein</intervention_name>
    <description>40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.</description>
    <arm_group_label>Milk protein-carbohydrate-soy protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate-soy protein-milk protein</intervention_name>
    <description>40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.</description>
    <arm_group_label>Carbohydrate-soy protein-milk protein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Systolic BP of 120 to 159 mm Hg and diastolic BP of 80 to 95 mm Hg (average of 6
             measurements at 2 screening visits)

          2. Willing to participate in all aspects of the study

        Exclusion Criteria:

          1. Consumption of dietary protein greater than or equal to 1.63 grams/kg per day, as
             determined by two 24-hour dietary recalls

          2. Stage-2 or higher severe hypertension (systolic BP greater than or equal to 160 mm Hg
             and/or diastolic BP greater than or equal to 95 mm Hg)

          3. Use of antihypertensive medications or medications that affect BP

          4. History of clinical heart disease (e.g., angina/heart attack, coronary
             revascularization, heart failure, stroke/transient ischemic attack, peripheral
             arterial disease)

          5. Kidney disease (serum creatinine level greater than or equal to 1.7 mg/dL for men and
             greater than or equal to 1.5 mg/dL for women)

          6. Current hypercholesterolemia (fasting serum total cholesterol greater than or equal to
             240 mg/dL) or use of cholesterol-lowering medications

          7. Current diabetes (fasting serum glucose greater than or equal to 126 mg/dL) or use of
             insulin or oral hypoglycemic agents

          8. Severe obesity (body mass index greater than or equal to 40 kg/mÂ²)

          9. Current use of prescription weight loss medications, underwent weight loss surgery,
             and/or experienced weight loss greater than 15 pounds within the 6 months prior to
             study entry

         10. Cancer (except non-melanoma skin cancer) that required treatment during the year prior
             to study entry

         11. Consumption of more than 14 alcoholic beverages per week

         12. Current participation in another medical study

         13. Consumption of milk or soy protein greater than or equal to the 90th percentile of
             intake in the U.S. general population

         14. Has another member of the household participating in the study

         15. Study employees or living with study employees

         16. Allergy or intolerance to soy protein or milk protein products

         17. Allergy to aspartame

         18. Plans to move out of the study area (greater than or equal to 50 miles from the study
             site) and has difficulty coming to the study site

         19. Inability or unwillingness to cooperate during the screening visits

         20. Poor compliance during the screening period (intake of less than 85% of supplements)

         21. Pregnant or plans to become pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang He, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <reference>
    <citation>Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23.</citation>
    <PMID>15652604</PMID>
  </reference>
  <results_reference>
    <citation>He J, Wofford MR, Reynolds K, Chen J, Chen CS, Myers L, Minor DL, Elmer PJ, Jones DW, Whelton PK. Effect of dietary protein supplementation on blood pressure: a randomized, controlled trial. Circulation. 2011 Aug 2;124(5):589-95. doi: 10.1161/CIRCULATIONAHA.110.009159. Epub 2011 Jul 18.</citation>
    <PMID>21768541</PMID>
  </results_reference>
  <results_reference>
    <citation>Wofford MR, Rebholz CM, Reynolds K, Chen J, Chen CS, Myers L, Xu J, Jones DW, Whelton PK, He J. Effect of soy and milk protein supplementation on serum lipid levels: a randomized controlled trial. Eur J Clin Nutr. 2012 Apr;66(4):419-25. doi: 10.1038/ejcn.2011.168. Epub 2011 Sep 28.</citation>
    <PMID>21952693</PMID>
  </results_reference>
  <results_reference>
    <citation>Rebholz CM, Reynolds K, Wofford MR, Chen J, Kelly TN, Mei H, Whelton PK, He J. Effect of soybean protein on novel cardiovascular disease risk factors: a randomized controlled trial. Eur J Clin Nutr. 2013 Jan;67(1):58-63. doi: 10.1038/ejcn.2012.186. Epub 2012 Nov 28.</citation>
    <PMID>23187956</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 7, 2005</study_first_submitted>
  <study_first_submitted_qc>April 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2005</study_first_posted>
  <results_first_submitted>November 30, 2016</results_first_submitted>
  <results_first_submitted_qc>June 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2018</results_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Pressure; Lipids; Dietary Protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Soy Protein-milk Protein-carbohydrate</title>
          <description>Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Milk Protein-carbohydrate-soy Protein</title>
          <description>Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Carbohydrate-soy Protein-milk Protein</title>
          <description>Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1 (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2 (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 3 (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants randomized to this three-phase cross-over trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Soy Protein-milk Protein-carbohydrate</title>
          <description>Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Milk Protein-carbohydrate-soy Protein</title>
          <description>Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Carbohydrate-soy Protein-milk Protein</title>
          <description>Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="118"/>
            <count group_id="B4" value="352"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.4" spread="11.5"/>
                    <measurement group_id="B2" value="46.7" spread="10.7"/>
                    <measurement group_id="B3" value="48.1" spread="8.7"/>
                    <measurement group_id="B4" value="47.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127.2" spread="9.3"/>
                    <measurement group_id="B2" value="126.7" spread="11.0"/>
                    <measurement group_id="B3" value="126.1" spread="9.7"/>
                    <measurement group_id="B4" value="126.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Systolic Blood Pressure at 8 Weeks</title>
        <description>The change of systolic blood pressure was calculated as the mean of 6 blood pressure values from two 8-week visits minus the mean of 6 values from 2 baseline visits within each intervention phase. At each visit, 3 BP values were measured with a Hawksley random-zero sphygmomanometer by trained and certified observers who were masked to group assignment. BP readings were taken from the right arm with appropriately sized cuffs after the participant had been seated quietly for 5 minutes. The participant was instructed not to eat, smoke, drink alcohol, or exercise for at least 30 minutes before their BP measurements.</description>
        <time_frame>Baseline and 8 Weeks</time_frame>
        <population>We conducted analysis according to intention-to-treat principle. All participants with data were included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Soy Protein Supplementation</title>
            <description>Cross-over analysis of soy protein supplementation</description>
          </group>
          <group group_id="O2">
            <title>Milk Protein Supplementation</title>
            <description>Cross-over analysis of milk protein supplementation</description>
          </group>
          <group group_id="O3">
            <title>Carbohydrate Supplementation</title>
            <description>Cross-over analysis of milk protein supplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Systolic Blood Pressure at 8 Weeks</title>
          <description>The change of systolic blood pressure was calculated as the mean of 6 blood pressure values from two 8-week visits minus the mean of 6 values from 2 baseline visits within each intervention phase. At each visit, 3 BP values were measured with a Hawksley random-zero sphygmomanometer by trained and certified observers who were masked to group assignment. BP readings were taken from the right arm with appropriately sized cuffs after the participant had been seated quietly for 5 minutes. The participant was instructed not to eat, smoke, drink alcohol, or exercise for at least 30 minutes before their BP measurements.</description>
          <population>We conducted analysis according to intention-to-treat principle. All participants with data were included in analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-2.4" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-2.7" upper_limit="-1.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-0.4" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum LDL-cholesterol at 8 Weeks</title>
        <description>Change in serum LDL-cholesterol was calculated as LDL-cholesterol at 8 weeks minus LDL-cholesterol at baseline. Over-night fasting serum LDL-cholesterol was measured with an enzymatic method.</description>
        <time_frame>Baseline and 8 Weeks</time_frame>
        <population>All participants with lipid data</population>
        <group_list>
          <group group_id="O1">
            <title>Soy Protein Supplementation</title>
            <description>Cross-over analysis of soy protein supplementation</description>
          </group>
          <group group_id="O2">
            <title>Milk Protein Supplementation</title>
            <description>Cross-over analysis of milk protein supplementation</description>
          </group>
          <group group_id="O3">
            <title>Carbohydrate Supplementation</title>
            <description>Cross-over analysis of milk protein supplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum LDL-cholesterol at 8 Weeks</title>
          <description>Change in serum LDL-cholesterol was calculated as LDL-cholesterol at 8 weeks minus LDL-cholesterol at baseline. Over-night fasting serum LDL-cholesterol was measured with an enzymatic method.</description>
          <population>All participants with lipid data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.97" lower_limit="-7.63" upper_limit="-0.31"/>
                    <measurement group_id="O2" value="-2.56" lower_limit="-5.40" upper_limit="0.28"/>
                    <measurement group_id="O3" value="-1.41" lower_limit="-4.24" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight at 8 Weeks</title>
        <description>Body weight was measured by trained staff using a standard protocol at week 8.</description>
        <time_frame>Baseline and 8 Weeks</time_frame>
        <population>All participants with body weight measures at each intervention phase</population>
        <group_list>
          <group group_id="O1">
            <title>Soy Protein Supplementation</title>
            <description>Cross-over analysis of soy protein supplementation</description>
          </group>
          <group group_id="O2">
            <title>Milk Protein Supplementation</title>
            <description>Cross-over analysis of milk protein supplementation</description>
          </group>
          <group group_id="O3">
            <title>Carbohydrate Supplementation</title>
            <description>Cross-over analysis of milk protein supplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight at 8 Weeks</title>
          <description>Body weight was measured by trained staff using a standard protocol at week 8.</description>
          <population>All participants with body weight measures at each intervention phase</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="286"/>
                <count group_id="O3" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="84.4" upper_limit="88.0"/>
                    <measurement group_id="O2" value="86.6" lower_limit="84.9" upper_limit="88.4"/>
                    <measurement group_id="O3" value="86.7" lower_limit="84.9" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 24 weeks</time_frame>
      <desc>This is a three-phase cross-over trial: 284 participants completed soy protein supplementation, 286 completed milk protein supplementation, and 287 completed carbohydrate supplementation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Soy Protein Supplementation</title>
          <description>Cross-over analysis of soy protein supplementation</description>
        </group>
        <group group_id="E2">
          <title>Milk Protein Supplementation</title>
          <description>Cross-over analysis of milk protein supplementation</description>
        </group>
        <group group_id="E3">
          <title>Carbohydrate Supplementation</title>
          <description>Cross-over analysis of milk protein supplementation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jiang He, MD, PhD, Chair of Epidemiology</name_or_title>
      <organization>Tulane University</organization>
      <phone>504-988-5165</phone>
      <email>jhe@tulane.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

